What's Happening?
A significant study conducted by the University of Nebraska Medical Center (UNMC) has revealed a potential link between the use of certain medications during pregnancy and an increased risk of autism spectrum disorder (ASD) in children. The research,
published in Molecular Psychiatry, analyzed 6.14 million maternal-child health records from the Epic Cosmos database, covering nearly one-third of all U.S. births from 2014 to 2023. The study focused on medications that inhibit the cholesterol synthesis pathway, including antidepressants, antipsychotics, anxiolytics, beta-blockers, and statins. These medications, known as sterol biosynthesis–inhibiting medications (SBIMs), were associated with a 1.47-fold higher risk of ASD in children when prescribed during pregnancy. The risk increased with the number of SBIMs prescribed, reaching a 2.33-fold risk when four or more were used simultaneously.
Why It's Important?
The findings of this study are crucial as they highlight a potential public health concern regarding the prescription of certain medications during pregnancy. Cholesterol is vital for fetal brain development, and disruptions in its synthesis can have significant neurodevelopmental consequences. The study suggests that even small biochemical disruptions during pregnancy can have outsized effects on fetal brain development, raising questions about the safety of these medications for pregnant women. This research could lead to a reevaluation of prescribing practices and the development of safer alternatives for use during pregnancy, potentially impacting millions of prescriptions annually in the U.S.
What's Next?
The research team has proposed several actions to improve drug safety for pregnant patients. These include creating a comprehensive list of medications with sterol-inhibiting effects, evaluating new pharmaceuticals for unintended sterol pathway inhibition, and increasing provider education about medication-associated sterol disruption during pregnancy. Additionally, the study calls for identifying patients with genetic vulnerabilities in sterol metabolism and investing in further research to understand the mechanisms and mitigate risks. These steps aim to ensure safer medication practices for pregnant women and reduce the risk of ASD in children.
